Patient Profile: 40-year-old female presenting with: Morbid obesity Newly diagnosed Type 2 Diabetes Mellitus Mixed dyslipidemia MASLD Positive history of gestational diabetes Strong family history of Type 2 Diabetes & cardiovascular disease Baseline Clinical Status: Weight: 96 kg HbA1c: 9.8% Random Blood Glucose: 380 mg/dL Blood Pressure: 130/85 mmHg LDL-C: 188 mg/dL Triglycerides: 396 mg/dL Liver Enzymes: Elevated ALT: 65 U/L AST: 46 U/L GGT: 93 U/L Comprehensive Treatment Strategy: Intensive lifestyle modification Empagliflozin + Metformin XR (25/1000 mg) Rosuvastatin + Ezetimibe (10/10 mg) Therapeutic Escalation Tirzatrim (Tirzepatide) was introduced 4.5 months ago, initiated at 2.5 mg once weekly and gradually titrated to 7.5 mg once weekly, while continuing background cardiometabolic therapy
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine
Of note, significant effects of GLP-2 and GLP-1 on hepatic regeneration have been described in rodent models of partial hepatectomy, suggesting a pro-regenerative role of GLP-2 10 , whereas GLP-1 seems to deteriorate post-hepatectomy liver regeneration 11
Detailed guidance on alcohol and tirzepatide and alcohol and semaglutide covers the nuances
Body composition changes reduced fat, improved muscle response generally become apparent between 36 months
Proceedings of the Human Factors and Ergonomics Society Annual Meeting, 69(1): 2049-2054
